Artigos de revistas: "Biochemical markers"

1

Ahmed, Mohamed H. "Biochemical Markers". American Journal of Clinical Pathology 127, n.º 1 (janeiro de 2007): 20–22. http://dx.doi.org/10.1309/jxwum661t8vt1etx.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Rothstein, Jeffrey. "Biochemical markers: Pro". Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 3, sup1 (setembro de 2002): S81. http://dx.doi.org/10.1080/146608202320374381.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Mitsumoto, Hiroshi. "Biochemical markers: Con". Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 3, sup1 (setembro de 2002): S83. http://dx.doi.org/10.1080/146608202320374390.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Strong, Michael J. "Biochemical markers: Summary". Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 3, sup1 (setembro de 2002): S85—S90. http://dx.doi.org/10.1080/146608202320374408.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Sandberg, Dr K. "3. Biochemical markers". Animal Genetics 20, n.º 1 (24 de abril de 2009): 56–83. http://dx.doi.org/10.1111/j.1365-2052.1989.tb01910.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Seishima, Mitsuru, Makiko Suzuki e Satoshi Maeda. "Atherosclerosis and biochemical markers." SEIBUTSU BUTSURI KAGAKU 48, n.º 4 (2004): 143–46. http://dx.doi.org/10.2198/sbk.48.143.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Selroos, Olof B. N. "Biochemical Markers in Sarcoidosis". CRC Critical Reviews in Clinical Laboratory Sciences 24, n.º 3 (janeiro de 1986): 185–216. http://dx.doi.org/10.3109/10408368609110273.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Đerić, Mirjana, Sunčica Kojić-Damjanov, Velibor Čabarkapa e Nevena Eremić. "Biochemical Markers of Atherosclerosis". Journal of Medical Biochemistry 27, n.º 2 (1 de janeiro de 2008): 148–53. http://dx.doi.org/10.2478/v10011-008-0008-1.

Texto completo da fonte

Resumo:

Biochemical Markers of AtherosclerosisThis paper is a brief review of some lipid parameters and serum markers of inflammation in a view of their predictive relevance for the atherosclerotic disease. A discourse on the importance of measuring different lipids and lipoproteins, concentration of LDL particles and apolipoprotein levels is still underway. Also, the recommendations for apolipoprotein (a), phenotypization and other lipid markers have not yet been established. In recent years the recommendations imply simultaneous measuring of multiple markers and calculating the lipid index values such as lipid tetrad index (LTI), lipid pentad index (LPI) and atherogenic index of plasma (AIP). Several circulating markers of inflammation such as C-reactive protein, serum fibrinogen and elevated leukocyte number, are consistently associated with atherosclerosis. In spite of a lack of evidence on measuring the C-reactive protein in a wide population, the guidelines for its application in diagnostics and therapy of coronary heart disease were developed. Some proinflammatory cytokines, adhesion molecules and markers of leukocyte activation are promising markers, requiring, however, more detailed prospective evaluation. The question to be elucidated is if these inflammatory markers are directly involved in the pathogenic process.

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Kanis, John. "Biochemical markers in osteoporosis". Scandinavian Journal of Clinical and Laboratory Investigation 57 (1997): 6–11. http://dx.doi.org/10.3109/00365519709168303.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Ratcliffe, Anthony, e Markus J. Seibel. "Biochemical markers of osteoarthritis". Current Opinion in Rheumatology 2, n.º 5 (outubro de 1990): 770–76. http://dx.doi.org/10.1097/00002281-199002050-00014.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Kanis, John A. "Biochemical markers in osteoporosis". Scandinavian Journal of Clinical and Laboratory Investigation 57, sup227 (janeiro de 1997): 6–11. http://dx.doi.org/10.1080/00365519709168303.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Jung, Rex E., Ronald A. Yeo, Stephen J. Chiulli, Wilmer L. Sibbitt, David C. Weers, Blaine L. Hart e William M. Brooks. "Biochemical markers of cognition". NeuroReport 10, n.º 16 (novembro de 1999): 3327–31. http://dx.doi.org/10.1097/00001756-199911080-00014.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Ikizler, T. Alp. "Biochemical markers: Clinical aspects". Journal of Renal Nutrition 7, n.º 2 (abril de 1997): 61–64. http://dx.doi.org/10.1016/s1051-2276(97)90039-x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Paselk, R. "Biochemical Markers for Cancer". Biochemical Education 13, n.º 1 (janeiro de 1985): 43. http://dx.doi.org/10.1016/0307-4412(85)90154-2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Stadtman, E. R. "Biochemical markers of aging". Experimental Gerontology 23, n.º 4-5 (janeiro de 1988): 327–47. http://dx.doi.org/10.1016/0531-5565(88)90036-8.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Samoilova, I. G., M. V. Matveeva e D. E. Galyukova. "Biochemical markers of autism". Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 124, n.º 1 (2024): 55. http://dx.doi.org/10.17116/jnevro202412401155.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Duffy, M. J. "Biochemical markers as prognostic indices in breast cancer". Clinical Chemistry 36, n.º 2 (1 de fevereiro de 1990): 188–91. http://dx.doi.org/10.1093/clinchem/36.2.188.

Texto completo da fonte

Resumo:

Abstract Traditional prognostic markers in breast cancer include histological variables such as tumor size, grade, and axillary node status. In recent years some new potential prognostic markers of a biochemical nature have been described: estradiol receptors, progesterone receptors, epidermal growth factor receptors, erbB-2 proto-oncogene, and certain proteolytic enzymes. None of these new markers excels axillary node status as a prognostic marker. Biochemical markers can, however, be evaluated with use of minimal surgery and may help distinguish the minority of aggressive axillary-node-negative breast cancers.

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Watts, Nelson B. "Clinical Utility of Biochemical Markers of Bone Remodeling". Clinical Chemistry 45, n.º 8 (1 de agosto de 1999): 1359–68. http://dx.doi.org/10.1093/clinchem/45.8.1359.

Texto completo da fonte

Resumo:

Abstract Remodeling is essential for bone health. It begins with resorption of old bone by osteoclasts, followed by the formation of new bone by osteoblasts. Remodeling is coupled (formation is linked to resorption). After middle age or perhaps beginning earlier, bone loss occurs because resorption exceeds formation. This imbalance is accentuated by estrogen deficiency as well as by many diseases and conditions. Biochemical markers that reflect remodeling and can be measured in blood or urine include resorption markers (e.g., collagen cross-links) and formation markers (e.g., alkaline phosphatase). Bone markers exhibit substantial short-term and long-term fluctuations related to time of day, phase of the menstrual cycle, and season of the year, as well as diet, exercise, and anything else that alters bone remodeling. These biological factors, in addition to assay imprecision, produce significant intra- and interindividual variability in markers. Bone marker measurements are noninvasive, inexpensive, and can be repeated often. Unfortunately, most of the studies that provided insight on clinical situations did not focus on markers as a primary endpoint. Bone markers have been useful in clinical practice and have been helpful in understanding the pathogenesis of osteoporosis and the mechanism of action of therapies. In clinical trials, markers aid in selecting optimal dose and in understanding the time course of onset and resolution of treatment effect. Clinical questions that might be answered by bone markers include diagnosing osteoporosis, identifying “fast bone losers” and patients at high risk of fracture, selecting the best treatment for osteoporosis, and providing an early indication of the response to treatment. Additional information is needed to define specific situations and cut points to allow marker results to be used with confidence in making decisions about individual patients.

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Cheung, K. L., S. E. Pinder, C. Paish, A. H. Sadozye, S. Y. Chan, A. J. Evans, R. W. Blamey e J. F. R. Robertson. "The Role of Blood Tumor Marker Measurement (Using a Biochemical Index Score and C-Erbb2) in Directing Chemotherapy in Metastatic Breast Cancer". International Journal of Biological Markers 15, n.º 3 (julho de 2000): 203–9. http://dx.doi.org/10.1177/172460080001500310.

Texto completo da fonte

Resumo:

The role of blood tumor markers in monitoring response in advanced breast cancer is established in endocrine therapy and standard chemotherapy. This study examines marker levels in patients receiving new chemotherapy regimens. Thirty patients were recruited into two multicenter trials in which docetaxel-based regimens were used in 15 patients. The other 15 received doxorubicin-based regimens. Biochemical response calculated from a score using CA15.3, CEA and ESR was compared with UICC response. Marker changes at 2, 4 and 5 months correlated with UICC response at 3, 41/2 and 6 months, respectively (p < 0.03). Eleven patients achieved both clinical/radiological and biochemical response at the end of treatment; markers had not yet returned to below cutoffs in seven, suggesting a possible advantage to continue chemotherapy. No patient showed a biochemical response whilst judged clinically/radiologically progressive. Nineteen patients had progressed either clinically/radiologically or biochemically at six months; of these, eight showed progression assessed earlier by markers so that a median of four cycles of chemotherapy could have been saved. Measurements of serum c-erbB2 showed a correlation with tissue c-erbB2 staining in the primary tumor (p < 0.003). Among the patients with positive tissue staining, sequential changes in serum c-erbB2 completely paralleled initial response.

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Zaitseva, O. V. "Biochemical markers of bone collagen type I metabolism". Ukrainian Biochemical Journal 87, n.º 1 (27 de fevereiro de 2015): 21–32. http://dx.doi.org/10.15407/ubj87.01.021.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Franco, Leonardo, e Mario Alejandro Ortíz Salazar. "Biochemical markers of bone metabolism". Revista Estomatología 18, n.º 1 (28 de setembro de 2017): 30–34. http://dx.doi.org/10.25100/re.v18i1.5707.

Texto completo da fonte

Resumo:

The quantity and quality of bone tissue renewal are dependent on the generation of new bone (deposition) mediated by osteoblasts and the loss (resorption) mediated by osteoclasts. For each of these processes there are important markers that can be measured in serum or urine. Resorption markers are products of metabolic degradation of bone matrix in particu-lar of the type I collagen (hydroxyproline, pyridinoline and deoxypyridinoline). In addition, the resorptive activity can also be evaluated through the tartrate resistant acid phosphatase (TRAP) and calcium-creatinine ratio in urine. Bone formation markers are collagen proteins (ALP, OCN), non collagen (ONC, OPN, BSP) or fragments of collagen synthesis (procollagen peptides).

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Rosen, Clifford J., e Alan Tenenhouse. "Biochemical markers of bone turnover". Postgraduate Medicine 104, n.º 4 (outubro de 1998): 101–14. http://dx.doi.org/10.3810/pgm.1998.10.447.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Accomando, Salvatore. "Biochemical markers in Celiac disease". Frontiers in Bioscience S2, n.º 1 (2010): 313–17. http://dx.doi.org/10.2741/s66.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Bapayeva, G. B. "Biochemical markers of premature birth". Journal of obstetrics and women's diseases 54, n.º 3 (1 de novembro de 2005): 38–41. http://dx.doi.org/10.17816/jowd83449.

Texto completo da fonte

Resumo:

Summary: In this article the results of the research of diagnostic importance of myoglobin determination in peripheral blood and amniotic fluid, fetal fibronectin examination in cervicovaginal composition contents of a pregnant woman are represented in prediction of premature birth.

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Koshul’ko, P. A., M. S. Kovalenko, Yu V. Abalenihina, A. I. Mirov, O. E. Golofast e E. D. Rokunov. "Biochemical markers of missed pregnancy". Problemy reproduktsii 27, n.º 6 (2021): 138. http://dx.doi.org/10.17116/repro202127061138.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Lyubimova, N. V., e N. E. Kushlinskiy. "Biochemical markers of bone metastasis". Advances in molecular oncology 2, n.º 1 (2 de junho de 2015): 061. http://dx.doi.org/10.17650/2313-805x.2015.2.1.061-075.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Lyubimova, N. V., e N. E. Kushlinskiy. "Biochemical markers of bone metastasis". Advances in molecular oncology 2, n.º 1 (2 de junho de 2015): 061. http://dx.doi.org/10.17650/2313-805x.2015.2.1.61-75.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Kovářů, H., F. Kovářů, A. Fišerová, P. Zelníčková e E. Matalová. "Biochemical Markers of Lymphocyte Maturation". Acta Veterinaria Brno 71, n.º 4 (2002): 503–8. http://dx.doi.org/10.2754/avb200271040503.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Delmas, Pierre D. "Biochemical markers of bone turnover". Acta Orthopaedica Scandinavica 66, sup266 (janeiro de 1995): 176–82. http://dx.doi.org/10.3109/17453679509157687.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Griesmacher, A., P. Peichl, P. Pointinger, R. Mateau e H. Broll. "Biochemical markers in menopausal women". Scandinavian Journal of Clinical and Laboratory Investigation 57 (1997): 64–72. http://dx.doi.org/10.3109/00365519709168309.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Apple, Fred. "Biochemical markers of thrombolytic success". Scandinavian Journal of Clinical and Laboratory Investigation 59 (1999): 60–66. http://dx.doi.org/10.3109/00365519909168328.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Kemp, M., J. Donovan, H. Higham e J. Hooper. "Biochemical markers of myocardial injury". British Journal of Anaesthesia 93, n.º 1 (julho de 2004): 63–73. http://dx.doi.org/10.1093/bja/aeh148.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Kerrigan, Richard W., e Ian K. Ross. "Extracellular Laccases: Biochemical Markers forAgaricusSystematics". Mycologia 80, n.º 5 (setembro de 1988): 689–95. http://dx.doi.org/10.1080/00275514.1988.12025602.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Lyubimova, N. V., T. K. Churikova, M. G. Toms e N. E. Kushlinskiy. "BIOCHEMICAL MARKERS OF NEUROENDOCRINAL TUMORS". Tambov University Reports. Series: Natural and Technical Sciences 21, n.º 2 (2016): 494–510. http://dx.doi.org/10.20310/1810-0198-2016-21-2-494-510.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Krstic, Danijela, Nenad Tomic, Branimir Radosavljevic, Natasa Avramovic, Vesna Dragutinovic, Sanja Radojevic Skodric e Mirjana Colovic. "Biochemical Markers of Renal Function". Current Medicinal Chemistry 23, n.º 19 (19 de julho de 2016): 2018–40. http://dx.doi.org/10.2174/0929867323666160115130241.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Demers, Laurence M., Luis Costa e Allan Lipton. "Biochemical Markers and Skeletal Metastases". Clinical Orthopaedics and Related Research 415 (outubro de 2003): S138—S147. http://dx.doi.org/10.1097/01.blo0000092979.12414.54.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Thompson, R. P. H. "Biochemical markers of liver disease". Current Opinion in Gastroenterology 1, n.º 3 (maio de 1985): 377–89. http://dx.doi.org/10.1097/00001574-198505000-00002.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Matull, W. R. "Biochemical markers of acute pancreatitis". Journal of Clinical Pathology 59, n.º 4 (1 de abril de 2006): 340–44. http://dx.doi.org/10.1136/jcp.2002.002923.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Engler, H., B. Thürlimann e F. Riesen. "Biochemical Markers of Bone Remodelling". Oncology Research and Treatment 19, n.º 2 (1996): 126–31. http://dx.doi.org/10.1159/000218778.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Griesmacher, A., P. Peichl, P. Pointinger, R. Mateau e H. Bröll. "Biochemical markers in menopausal women". Scandinavian Journal of Clinical and Laboratory Investigation 57, sup227 (janeiro de 1997): 64–72. http://dx.doi.org/10.1080/00365519709168309.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Apple, Fred S. "Biochemical markers of thrombolytic success". Scandinavian Journal of Clinical and Laboratory Investigation 59, sup230 (janeiro de 1999): 60–66. http://dx.doi.org/10.1080/00365519909168328.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Gao, F., e D. N. F. Harris. "Biochemical markers of cerebral damage". European Journal of Anaesthesiology 14, n.º 2 (março de 1997): 113–17. http://dx.doi.org/10.1097/00003643-199703000-00001.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

De Jongh, R., C. De Deyne, G. Kenis, G. Vundelinckx, L. Merckx e R. Heylen. "Biochemical markers of brain ischaemia". European Journal of Anaesthesiology 15, Supplement 17 (janeiro de 1998): 14–15. http://dx.doi.org/10.1097/00003643-199801001-00011.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Crofton, P. M., H. F. Stirling, E. Schönau, S. F. Ahmed, W. H. B. Wallace, J. C. Wade, R. Magowan et al. "Biochemical Markers of Bone Turnover". Hormone Research 45, n.º 1 (1996): 55–58. http://dx.doi.org/10.1159/000184832.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Rambotti, Pietro. "Biochemical markers in lymphoproliferative diseases". Critical Reviews in Oncology/Hematology 2, n.º 4 (janeiro de 1985): 297–321. http://dx.doi.org/10.1016/s1040-8428(85)80006-8.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Shepherd, J. "Biochemical risk markers of CHD". Atherosclerosis 144 (maio de 1999): 144. http://dx.doi.org/10.1016/s0021-9150(99)80558-9.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Seibel, Markus J. "Biochemical markers of bone remodeling". Endocrinology and Metabolism Clinics of North America 32, n.º 1 (março de 2003): 83–113. http://dx.doi.org/10.1016/s0889-8529(02)00077-4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Garnero, Patrick, e Pierre D. Delmas. "BIOCHEMICAL MARKERS OF BONE TURNOVER". Endocrinology and Metabolism Clinics of North America 27, n.º 2 (junho de 1998): 303–23. http://dx.doi.org/10.1016/s0889-8529(05)70007-4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Gavaghan, Mary. "Biochemical Markers in Myocardial Injury". AORN Journal 70, n.º 5 (novembro de 1999): 839–54. http://dx.doi.org/10.1016/s0001-2092(06)61303-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Yuasa, Isao, e Kazuo Umetsu. "Molecular aspects of biochemical markers". Legal Medicine 7, n.º 4 (julho de 2005): 251–54. http://dx.doi.org/10.1016/j.legalmed.2004.12.001.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Artigos de revistas sobre o tema "Biochemical markers"

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos